Swedish Orphan Biovitrum ABSWOBY 67 Gross Margin % is 75.69% as of Mar. 2026, which is 2% below its 10-year median of 77.01. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $17.17 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 938 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks better than 90.09% on this metric.
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Swedish Orphan Biovitrum AB had a gross margin of 75.69% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Swedish Orphan Biovitrum AB Gross Margin % Related Terms
Swedish Orphan Biovitrum AB Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Swedish Orphan Biovitrum AB (SWOBY) has a Gross Margin % of 75.69% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Swedish Orphan Biovitrum AB and its competitors. This is near median its historical median of 77.01. Over the past decade, Swedish Orphan Biovitrum AB's Gross Margin % has ranged from 70.14 to 78.87. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #93 out of 938 companies in the Drug Manufacturers industry, placing it in the top 9.9%.
Is Swedish Orphan Biovitrum AB's Gross Margin % too high?
Swedish Orphan Biovitrum AB's current Gross Margin % of 75.69% is near median its 10-year median of 77.01. Over the past 10 years, this metric has ranged from a low of 70.14 to a high of 78.87. The Drug Manufacturers industry median Gross Margin % is 48.44. Swedish Orphan Biovitrum AB's value of 75.69% is 56.3% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #93 out of 938 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #93 out of 938 companies for Gross Margin %. This places Swedish Orphan Biovitrum AB in the top 10% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.44. Swedish Orphan Biovitrum AB's value of 75.69% is 56.3% above this benchmark. Historically, Swedish Orphan Biovitrum AB's own Gross Margin % has ranged from 70.14 to 78.87 over the past decade. While the company's 10-year median is 77.01 vs. the industry median of 48.44, Swedish Orphan Biovitrum AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current Gross Margin % of 75.69% is 56.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current Gross Margin % is 75.69%, which is near median its own 10-year median of 77.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $17.17, compared to a current price of $23.18 — trading 35% above its estimated fair value. The current Gross Margin % is 75.69%, which is near median its 10-year median of 77.01 and 56.3% above the Drug Manufacturers industry median of 48.44. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current Gross Margin % is 75.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $23.18 is trading 35% above its estimated GF Value™ of $17.17.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for SWOBY:
Gross Margin %: 75.69% (near median its 10-year median of 77.01)
GF Value™: $17.17 vs. price of $23.18 (35% above fair value)
Industry Position: 56.3% above the Drug Manufacturers median (#93 of 938)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
